“The good thing is that, at least now, there is this huge interest in primary mitochondrial diseases, so more companies are working in the space,” says Jan Smeitink, CEO of Khondrion. “It’s also good to notice that different companies have compounds working on different targets.”
Tag Archive for: Friedreich’s ataxia
Shares of Reata Pharmaceuticals Inc. soared 175% to hit a one-year high in early trading on Wednesday, after the U.S. Food and Drug Administration (FDA) approved its rare disease drug and ended years of uncertainty over its future.
There are currently no disease-modifying treatments for Friedreich’s ataxia. That could change when the FDA makes a decision about Reata Pharmaceuticals’ omaveloxolone on Feb. 28.
